Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

2005 • 6,591 citations

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

1996 • 5,667 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry

2005 • 805 citations

CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival

1979 • 478 citations

Clinical Relevance of MGMT in the Treatment of Cancer

2002 • 415 citations

O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

2008 • 371 citations

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

2010 • 371 citations

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

2003 • 365 citations

Alkylating agents in bronchogenic carcinoma

1969 • 353 citations

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

2004 • 317 citations

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

2007 • 260 citations

DNA methylation profiles of lung tumors.

2001 • 233 citations

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

2006 • 227 citations

Chemopotentiation by PARP inhibitors in cancer therapy

2005 • 183 citations

RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).

2011 • 121 citations

Inhibition of poly(ADP-ribose) polymerase in cancer

2006 • 107 citations

Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.

1998 • 106 citations

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

2005 • 78 citations

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

2008 • 78 citations

Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter

2007 • 74 citations

Hematologic adverse events associated with temozolomide

2011 • 55 citations

High-Throughput Hacking of the Methylation Patterns in Breast Cancer by In vitro Transcription and Thymidine-Specific Cleavage Mass Array on MALDI-TOF Silico-Chip

2008 • 45 citations

Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia

2008 • 30 citations